Roots Analysis has done a detailed study on “Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways” covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

To order this 485+ page report, which features 195+ figures and 200+ tables, please visit this link

Key Market Insights
 An analysis of recent activity on Twitter confirms the rising interest in this domain as stakeholders attempt to harness the therapeutic potential of synthetic lethality
 About 75 drug candidates based on synlet gene pairs are being evaluated for the treatment of various types of cancers; presently, there are over 20 screening platforms enabling therapy development efforts
 The pipeline features both small molecules and biologic drugs based on different synlet targets for treating a variety of oncological and non-oncological indications
 Innovation in this domain is evident across the plethora of scientific articles published in prestigious journals, highlighting key focus areas and prevalent / upcoming trends
 Over time, several non-profit organizations have extended financial support to aid research efforts in this domain; the current focus appears to be on the identification of novel synlet targets across different clinical conditions
 Significant advances in research have led to the discovery of a wide array of synlet targets; over time, substantial intellectual capital has been generated and validated by eminent scientists from renowned research institutes
 To support innovation, several private and public investors have made substantial capital investments, totalling to approximately USD 5.1 billion, across 100 instances of funding
 The personalized approach offered by companion diagnostics presents enormous opportunities for drug developers to partner with diagnostic test providers to improve patient / subject selection in clinical trials
 Future growth of the market is likely to be driven by the success of clinical outcomes of late-stage molecules; industry stakeholders are optimistic about the vast potential of PARP inhibitors
 In the mid to long term, the anticipated market opportunity is likely to be well distributed across advanced cancer indications, delivery routes and various global regions

For more information, please visit https://www.rootsanalysis.com/reports/view_document/synthetic-lethality-based-drugs-and-targets-market-2019-2030-focus-on-dna-repair-including-parp-inhibitors-and-other-novel-cellular-pathways/267.html

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION TO DNA DAMAGE AND REPAIR SYSTEMS
3.1. Chapter Overview
3.2. Overview of Deoxyribonucleic Acid (DNA) Damage
3.3. DNA Damaging Agents
3.3.1. Endogenous DNA Damaging Agents
3.3.2. Exogenous DNA Damaging Agents
3.3.3. Other DNA Damaging Agents
3.4. DNA Damage Response System
3.4.1. Key Components of DNA Repair System

3.5. Types of DNA Repair Systems
3.5.1. Direct Repair
3.5.1.1. Photoreactivation
3.5.1.2. Alkyl Transferase Mediated Direct DNA Repair
3.5.1.3. AlkB Mediated Direct DNA Repair
3.5.1.4. DNA Ligase Mediated Direct DNA Repair

3.5.2. Excision Repair
3.5.2.1. Base Excision Repair (BER)
3.5.2.1.1. BER Pathway: Key Enzymes
3.5.2.1.1.1. DNA Glycosylases
3.5.2.1.1.2. Apurinic / Apyrimidinic (AP) Endonucleases
3.5.2.1.1.3. Other Enzymes
3.5.2.1.2. Short-Patch Base Excision Repair
3.5.2.1.3. Long-Patch Base Excision Repair
3.5.2.2. Nucleotide Excision Repair (NER)
3.5.2.3. Mismatch Repair

3.5.3. Indirect Repair
3.5.3.1. Homologous Recombination Repair (HRR)
3.5.3.2. Non-Homologous End-Joining

3.6. Mutations in DNA Repair Genes

4. INTRODUCTION TO SYNTHETIC LETHALITY
4.1. Chapter Overview
4.2. Concept of Synthetic Lethality
4.2.1. Historical Evolution of Synthetic Lethality
4.2.2. HRR and Synthetic Lethality
4.2.3. Other Synthetic Lethal Gene Interactions
4.2.4. Advantages of Synthetic Lethality
4.2.5. Limitations of Synthetic Lethality

4.3. Identification of Synlet Interactions
4.3.1. Hypothesis-Driven Approach
4.3.2. Screening-Based Approaches
4.3.2.1. Chemical Library-Based Screening Approaches
4.3.2.1.1. Non-Annotated Libraries
4.3.2.1.2. Annotated Libraries
4.3.2.2. Genome-Wide Interference-Based Screening Approaches
4.3.2.2.1. Ribonucleic Acid Interference (RNAi) Based Synlet Target Identification
4.3.2.2.2. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Based Synlet Target Identification
4.3.3. In Silico Approaches

4.4. Prevalent Trends Related to Synthetic Lethality
4.4.1. Recent News on Google: Emerging Focus Areas
4.4.2. Google Trends Analysis: Historical Timeline
4.4.3. Google Trends Analysis: Geographical Activity
4.4.4. Google Trends Analysis: Other Key Terms Related to Synthetic Lethality

4.5 Concluding Remarks

5. MARKET OVERVIEW
5.1. Chapter Overview
5.2. Synthetic Lethality-based Drugs: Marketed and Development Pipeline
5.2.1. Analysis by Phase of Development
5.2.2. Analysis by Type of Molecule
5.2.3. Analysis by Type of Therapy
5.2.4. Analysis by Type of Synlet Target
5.2.5. Analysis by Therapeutic Area
5.2.6. Analysis by Target Indication
5.2.7. Analysis by Patient Segment
5.2.8. Analysis by Route of Administration

5.3. Synthetic Lethality-based Drugs: List of Screening Platforms
5.4 Synthetic Lethality-based Drugs: List of Drug Developers / Screening Platform Providers
5.4.1. Analysis by Year of Establishment
5.4.2. Analysis by Location of Headquarters
5.4.3. Analysis by Company Size
5.4.4. Analysis by Company Size and Location of Headquarters
5.4.5. Leading Drug Developers

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Profiles of Established Players
6.2.1. AbbVie
6.2.1.1. Company Overview
6.2.1.2. Synthetic Lethality-based Drug Portfolio
6.2.1.2.1. Veliparib (ABT-888)
6.2.1.3. Recent Developments and Future Outlook

6.2.2. AstraZeneca
6.2.2.1. Company Overview
6.2.2.2. Synthetic Lethality-based Drug Portfolio
6.2.2.2.1. Olaparib (Lynparza®)
6.2.2.2.2. AZD6738
6.2.2.2.3. AZD1775
6.2.2.3. Recent Developments and Future Outlook

6.2.3. BeiGene
6.2.3.1. Company Overview
6.2.3.2. Synthetic Lethality-based Drug Portfolio
6.2.3.2.1. Pamiparib (BGB-290)
6.2.3.3. Recent Developments and Future Outlook

6.2.4. Clovis Oncology
6.2.4.1. Company Overview
6.2.4.2. Synthetic Lethality-based Drug Portfolio
6.2.4.2.1. Rucaparib (Rubraca®)
6.2.4.3. Recent Developments and Future Outlook

6.2.5. GlaxoSmithKline
6.2.5.1. Company Overview
6.2.5.2. Synthetic Lethality-based Drug Portfolio
6.2.5.2.1. Niraparib (Zejula®)
6.2.5.3. Recent Developments and Future Outlook

6.2.6. Pfizer
6.2.6.1. Company Overview
6.2.6.2. Synthetic Lethality-based Drug Portfolio
6.2.6.2.1. Talazoparib (TALZENNA®)
6.2.6.3. Recent Developments and Future Outlook

6.3. Profiles of Small and Mid-Sized Players
6.3.1. AtlasMedx
6.3.2. Chordia Therapeutics
6.3.3. IDEAYA Biosciences
6.3.4. Mission Therapeutics
6.3.5. Repare Therapeutics
6.3.6. Sierra Oncology
6.3.7. SyntheX Labs

7. EMERGING TRENDS ON SOCIAL MEDIA
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Synthetic Lethality: Trends on Twitter
7.3.1. Cumulative Year-Wise Activity
7.3.2. Historical Trends in Volume of Tweets
7.3.3. Evolutionary Trend Analysis
7.3.4. Trending Words / Phrases on Twitter
7.3.5. Most Prolific Contributors on Twitter
7.3.6. Most Popular Synlet Targets / Patient Mutations on Twitter
7.3.7. Most Popular Indications on Twitter
7.3.8. Heat Map Analysis: Distribution by Synlet Targets / Patient Mutations and Indications

7.4. Most Popular Tweets
7.5. Concluding Remarks

8. PUBLICATION ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology

8.3. Synthetic Lethality: List of Recent Publications, 2019
8.3.1. Analysis by Type of Publication
8.3.2. Analysis by Study Objective

8.4. Synthetic Lethality: Publication Analysis, 2017–2019
8.4.1. Analysis by Year of Publication

8.4.2. Emerging Focus Areas
8.4.3. Analysis by Synlet Targets / Patient Mutations
8.4.3.1. Most Popular Synlet Targets / Patient Mutations
8.4.3.2. Year-Wise Trend in Activity for Popular Synlet Targets / Patient Mutations
8.4.4. Analysis by Target Indications
8.4.4.1. Most Popular Target Indications
8.4.4.2. Year-Wise Trend in Activity for Popular Target Indications

8.4.5. Analysis by Key Research Journals
8.4.5.1. Key Journals Based on Number of Publications
8.4.5.2. Analysis by Journal Impact Factor
8.4.5.3. Key Journals Based on Journal Impact Factor

8.4.6. Key Research Hubs
8.4.7. Most Popular Authors

8.4.8. Analysis of Publications with Grant Support
8.4.8.1. Most Popular Grant Bodies
8.4.8.2. Location of Grant Bodies

8.5. Publication Benchmark Analysis

9. ABSTRACT ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology

9.3. Synthetic Lethality: List of American Society of Clinical Oncology Abstracts
9.3.1. Analysis by Year of Publication
9.3.2. Emerging Focus Areas
9.3.3. Most Popular Drugs
9.3.4. Most Popular Synlet Targets / Patient Mutations
9.3.5. Most Popular Target Indications
9.3.6. Most Popular Principal Authors
9.3.6.1. Analysis by Locations of Principal Authors
9.3.6.2. Analysis by Type of Organization of Principal Authors
9.3.6.3. Analysis by Active Organization
9.3.6.4. Analysis by Author Designation
9.3.6.5. Most Popular Authors

10. ACADEMIC GRANTS ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology

10.3. Synthetic Lethality: List of Grants Awarded by National Institutes of Health
10.3.1. Analysis by Year of Award
10.3.2. Analysis by Amount Awarded
10.3.3. Analysis by Administering Institute Center
10.3.4. Analysis by Funding Institute Center
10.3.5. Analysis by Support Period
10.3.6. Analysis by Funding Institute Center and Support Period
10.3.7. Most Popular National Institute of Health (NIH) Funding Categorization
10.3.8. Analysis by Funding Mechanism
10.3.9. Analysis by Emerging Focus Areas
10.3.10. Most Popular Synlet Targets / Patient Mutations
10.3.11. Most Popular Target Indications
10.3.12. Analysis by Type of Grant Application
10.3.13. Most Popular NIH Departments
10.3.14. Analysis by Study Section
10.3.15. Analysis by Type of Recipient Organization
10.3.16. Most Popular Recipient Organization
10.3.17. Most Popular Recipient Organization and NIH Spending Sectors
10.3.18. Analysis by Grant Activity
10.3.19. Most Prominent Program Officers
10.3.20. Regional Distribution of Recipient Organization

10.4. Grant Attractiveness Analysis

11. FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding

11.3. Synthetic Lethality: List of Funding and Investments
11.3.1. Analysis by Number of Instances
11.3.2. Analysis by Amount Invested
11.3.3. Analysis by Type of Funding
11.3.4. Analysis by Type of Company
11.3.5. Analysis by Purpose of Funding
11.3.6. Analysis by Type of Molecule
11.3.7. Analysis by Synlet Target
11.3.8. Analysis by Therapeutic Area
11.3.9. Analysis by Target Indication
11.3.10. Analysis by Geography
11.3.11. Most Active Players
11.3.12. Most Active Investors

11.4. Concluding Remarks

12. TARGET BENCHMARK ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Target Benchmark Analysis
12.3.1. Clinically Validated Synlet Targets
12.3.2. Preclinically Validated Synlet Targets
12.3.3. Early Stage Research Validated Synlet Targets
12.4. Initiatives of Big Pharmaceutical Players
12.5. Concluding Remarks

13. ROLE OF COMPANION DIAGNOSTICS IN SYNTHETIC LETHALITY
13.1. Chapter Overview
13.2. Concept of Companion Diagnostics
13.3. Development of Companion Diagnostics
13.3.1. Co-development / Parallel Development Approach
13.3.2. Development of Companion Diagnostics Post Drug Approval
13.3.3. Development of already Approved Companion Diagnostics for New Drugs / Disease Indications

13.4. Advantages of Companion Diagnostics
13.5. Applications of Companion Diagnostics in Synthetic Lethality

13.6. Companion Diagnostics: List of Available / Under Development Tests
13.6.1. Analysis by Synlet Target
13.6.2. Analysis by Type of Biomarker
13.6.3. Analysis by Type of Biomarker and Technology
13.6.4. Analysis by Target Indication
13.6.5. Analysis by Developer and Synlet Target
13.6.6. Most Prominent Developers

13.7. Case-in-Point: Companion Diagnostics for Commercially Available Poly-ADP Ribose Polymerase (PARP) Inhibitors
13.7.1. Companion Diagnostics Test for Niraparib
13.7.1.1. Product Overview
13.7.1.2. Working Process
13.7.1.3. Collaborations

13.7.2. Companion Diagnostics Test for Olaparib
13.7.2.1. Product Overview
13.7.2.2. Working Process
13.7.2.3. Collaborations

13.7.3. Companion Diagnostics Test for Rucaparib
13.7.3.1. Product Overview
13.7.3.2. Collaborations

13.7.4. Companion Diagnostics Test for Talazoparib
13.7.4.1. Product Overview
13.7.4.2. Collaborations

13.8. Future Perspective

14. MARKET FORECAST
14.1. Chapter Overview
14.2. Scope and Limitations
14.3. Forecast Methodology and Key Assumptions

14.4. Overall Synthetic Lethality-based Drugs Market, 2019-2030
14.4.1. Synthetic Lethality-based Drugs Market: Distribution by Type of Molecule, 2019 and 2030
14.4.1.1. Synthetic Lethality-based Drugs Market for Small Molecule, 2019-2030
14.4.1.2. Synthetic Lethality-based Drugs Market for Biologic, 2019-2030

14.4.2. Synthetic Lethality-based Drugs Market: Distribution by Synlet Target, 2019 and 2030
14.4.2.1. Synthetic Lethality-based Drugs Market for APE1 / REF-1, 2019-2030
14.4.2.2. Synthetic Lethality-based Drugs Market for CHK1, 2019-2030
14.4.2.3. Synthetic Lethality-based Drugs Market for GLS1, 2019-2030
14.4.2.4. Synthetic Lethality-based Drugs Market for PARP, 2019-2030
14.4.2.5. Synthetic Lethality-based Drugs Market for Polθ, 2019-2030
14.4.2.6. Synthetic Lethality-based Drugs Market for WEE1, 2019-2030

14.4.3. Synthetic Lethality-based Drugs Market: Distribution by Target Indication, 2019 and 2030
14.4.3.1. Synthetic Lethality-based Drugs Market for Breast Cancer, 2019-2030
14.4.3.2. Synthetic Lethality-based Drugs Market for Cervical / Anogenital Cancer, 2019-2030
14.4.3.3. Synthetic Lethality-based Drugs Market for Diabetic Macular Edema, 2019-2030
14.4.3.4. Synthetic Lethality-based Drugs Market for Gastric Cancer, 2019-2030
14.4.3.5. Synthetic Lethality-based Drugs Market for Lung Cancer, 2019-2030
14.4.3.5. Synthetic Lethality-based Drugs Market for Ovarian Cancer, 2019-2030
14.4.3.7. Synthetic Lethality-based Drugs Market for Renal Cell Cancer, 2019-2030

14.4.4. Synthetic Lethality-based Drugs Market: Distribution by Route of Administration, 2019 and 2030
14.4.4.1. Synthetic Lethality-based Drugs Market for Oral Therapies, 2019-2030
14.4.4.2. Synthetic Lethality-based Drugs Market for Intravenous Therapies, 2019-2030

14.4.5. Synthetic Lethality-based Drugs Market: Distribution by Geography, 2019 and 2030
14.4.5.1. Synthetic Lethality-based Drugs Market in the US, 2019-2030
14.4.5.2. Synthetic Lethality-based Drugs Market in France, 2019-2030
14.4.5.3. Synthetic Lethality-based Drugs Market in Germany, 2019-2030
14.4.5.4. Synthetic Lethality-based Drugs Market in Italy, 2019-2030
14.4.5.5. Synthetic Lethality-based Drugs Market in Spain, 2019-2030
14.4.5.6. Synthetic Lethality-based Drugs Market in the UK, 2019-2030
14.4.5.8. Synthetic Lethality-based Drugs Market in Australia, 2019-2030
14.4.5.7. Synthetic Lethality-based Drugs Market in China, 2019-2030
14.4.5.8. Synthetic Lethality-based Drugs Market in Japan, 2019-2030

14.4.6. Product-wise Sales Forecast
14.4.6.1 Niraparib (GlaxoSmithKline)
14.4.6.1.1. Target Patient Population
14.4.6.1.2. Sales Forecast (USD Million)
14.4.6.1.3. Net Present Value (USD Million)
14.4.6.1.4. Value Creation Analysis

14.4.6.2. Olaparib (AstraZeneca)
14.4.6.2.1. Target Patient Population
14.4.6.2.2. Sales Forecast (USD Million)
14.4.6.2.3. Net Present Value (USD Million)
14.4.6.2.4. Value Creation Analysis

14.4.6.3. Rucaparib (Clovis Oncology)
14.4.6.3.1. Target Patient Population
14.4.6.3.2. Sales Forecast (USD Million)
14.4.6.3.3. Net Present Value (USD Million)
14.4.6.3.4. Value Creation Analysis

14.4.6.4. Talazoparib (Pfizer)
14.4.6.4.1. Target Patient Population
14.4.6.4.2. Sales Forecast (USD Million)
14.4.6.4.3. Net Present Value (USD Million)
14.4.6.4.4. Value Creation Analysis

14.4.6.5. Pamiparib (BeiGene)
14.4.6.5.1. Target Patient Population
14.4.6.5.2. Sales Forecast (USD Million)
14.4.6.5.3. Net Present Value (USD Million)
14.4.6.5.4. Value Creation Analysis

14.4.6.6. Veliparib (AbbVie)
14.4.6.6.1. Target Patient Population
14.4.6.6.2. Sales Forecast (USD Million)
14.4.6.6.3. Net Present Value (USD Million)
14.4.6.6.4. Value Creation Analysis

14.4.6.7. Adavosertib (AstraZeneca)
14.4.6.7.1. Target Patient Population
14.4.6.7.2. Sales Forecast (USD Million)
14.4.6.7.3. Net Present Value (USD Million)
14.4.6.7.4. Value Creation Analysis

14.4.6.8. APX3330 (Apexian Pharmaceuticals)
14.4.6.8.1. Target Patient Population
14.4.6.8.2. Sales Forecast (USD Million)
14.4.6.8.3. Net Present Value (USD Million)
14.4.6.8.4. Value Creation Analysis

14.4.6.9. CX-5461 (Senhwa Biosciences)
14.4.6.9.1. Target Patient Population
14.4.6.9.2. Sales Forecast (USD Million)
14.4.6.9.3. Net Present Value (USD Million)
14.4.6.9.4. Value Creation Analysis

14.4.6.10. SRA737-01 (Sierra Oncology)
14.4.6.10.1. Target Patient Population
14.4.6.10.2. Sales Forecast (USD Million)
14.4.6.10.3. Net Present Value (USD Million)
14.4.6.10.4. Value Creation Analysis

14.4.6.11. SRA737-02 (Sierra Oncology)
14.4.6.11.1. Target Patient Population
14.4.6.11.2. Sales Forecast (USD Million)
14.4.6.11.3. Net Present Value (USD Million)
14.4.6.11.4. Value Creation Analysis

14.4.6.12. Telaglenastat (Calithera Biosciences)
14.4.6.12.1. Target Patient Population
14.4.6.12.2. Sales Forecast (USD Million)
14.4.6.12.3. Net Present Value (USD Million)
14.4.6.12.4. Value Creation Analysis

14.4.7. Concluding Remarks

15. CONCLUDING REMARKS

16. EXECUTIVE INSIGHTS
16.1. Chapter Overview
16.2. Artios Pharma
16.2.1. Company / Organization Snapshot
16.2.2. Interview Transcript: Simon Boulton, Vice President, Science Strategy

16.3. IMPACT Therapeutics
16.3.1. Company / Organization Snapshot
16.3.2. Interview Transcript: Yi Xu, Associate Director

16.4. Harvard Medical School
16.4.1. Company / Organization Snapshot
16.4.2. Interview Transcript: Norbert Perrimon, Professor, Department of Genetics

16.5. Panjab University
16.5.1. Company / Organization Snapshot
16.5.2. Interview Transcript: Vivek Dharwal, Professor, Department of Biochemistry

16.6. UbiQ
16.6.1. Company / Organization Snapshot
16.6.2. Interview Transcript: Alfred Nijkerk, Chief Executive Officer

17. APPENDIX 1: TABULATED DATA

18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]